CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
Capecitabine combined with lenvatinib and tislelizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05254847
NCT05254847Phase 2Completed
CompareCT.gov

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With Biliary Tract Cancer: A Single-arm, Phase II Study

Fudan University·interventional·Posted Feb 24, 2022·Updated Jan 20, 2026

In Brief

A Phase 2 clinical trial evaluating Capecitabine combined with lenvatinib and tislelizumab for Biliary Tract Cancer. Completed, enrolled 65 participants across 1 site.

Detailed Summary

This is a prospective, open-label, single-center clinical study, to evaluate the efficacy and safety of Capecitabine combined with Lenvatinib and Tislelizumab as adjuvant treatment after resection in patients with biliary tract cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Cancer
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedFeb 24, 2022
Enrollment StartFeb 24, 2022
Primary CompletionDec 31, 2023
Study CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.4 years ago

Interventions

Capecitabine combined with lenvatinib and tislelizumabdrug

Capecitabine combined with lenvatinib and tislelizumab